

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 18, 2017

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for August 10, 2017 meeting
- IV. Secretary's report
- V. Old Business
 - A. Update on approved pediatric protocols for Sovaldi[®] and Harvoni[®]
 - B. Dentists opioid utilization review report from Medicaid Fraud Department
 - C. PCSK9 utilization review
- VI. New Business
 - A. Proposed update to protocol for direct acting antivirals (DAAs) used in hepatitis C therapy
 - B. Proposed protocol for safe and efficient use of opioid induced constipation products
 - C. Proposed protocol for safe and efficient use of cerliponase alfa (Brineura[®])
 - D. Tenofovir disoproxil (TDF) versus tenofovir alafenamide (TAF)
- VII. DURB Annual Report for SFY 2017 (July 1 thru June 30)
- VIII. Informational Highlights/Reports
 1. Molina/NJ HMO 2nd Quarter 2017 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered drugs by amount paid/category
 4. Medication information:
 - (a) Proton Pump Inhibitors linked to increased risk of death
 - (b) Safety of Long-Term PPI Use
 - (c) Use of Fentanyl Patches in Nursing Homes Persists After FDA Warning
 - (d) Med Switch Not Always Best Choice With Tough Depression
 - (e) Study Confirms Link Between Med and Rare But Dangerous Complication
 - (f) Is FDA Taking Close Enough Look at Fast-Tracked Drugs?